KBC Group NV Sells 224,828 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

KBC Group NV trimmed its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 69.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 98,674 shares of the company’s stock after selling 224,828 shares during the period. KBC Group NV’s holdings in Elanco Animal Health were worth $1,036,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of ELAN. CoreCap Advisors LLC purchased a new position in shares of Elanco Animal Health during the fourth quarter valued at about $29,000. NBC Securities Inc. purchased a new stake in Elanco Animal Health in the first quarter worth about $40,000. Parallel Advisors LLC grew its holdings in Elanco Animal Health by 92.2% in the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company’s stock worth $41,000 after purchasing an additional 1,852 shares during the period. Versant Capital Management Inc grew its holdings in Elanco Animal Health by 65.9% in the first quarter. Versant Capital Management Inc now owns 4,382 shares of the company’s stock worth $46,000 after purchasing an additional 1,740 shares during the period. Finally, Jones Financial Companies Lllp lifted its stake in shares of Elanco Animal Health by 95.6% in the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock worth $51,000 after buying an additional 2,059 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Stock Down 0.5%

ELAN opened at $14.64 on Friday. The company has a current ratio of 2.71, a quick ratio of 1.46 and a debt-to-equity ratio of 0.68. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $15.78. The company has a market capitalization of $7.27 billion, a PE ratio of 19.78, a PEG ratio of 2.86 and a beta of 1.67. The firm’s 50 day simple moving average is $12.93 and its two-hundred day simple moving average is $11.59.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.31 by $0.06. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. Elanco Animal Health had a net margin of 8.43% and a return on equity of 7.54%. The company’s revenue was down 1.0% on a year-over-year basis. During the same period last year, the firm earned $0.34 EPS. As a group, equities analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ELAN. Stifel Nicolaus upped their target price on shares of Elanco Animal Health from $16.00 to $17.00 and gave the stock a “buy” rating in a research note on Wednesday. Wall Street Zen upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, William Blair upgraded shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating in a research report on Thursday, June 26th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Elanco Animal Health presently has an average rating of “Moderate Buy” and a consensus price target of $15.33.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.